Peroxisome proliferator-activated receptors (PPARs) and their agonists for hypertension and heart failure: are the reagents beneficial or harmful?

@article{Chen2008PeroxisomePR,
  title={Peroxisome proliferator-activated receptors (PPARs) and their agonists for hypertension and heart failure: are the reagents beneficial or harmful?},
  author={R. Chen and Fengxia Liang and J. Moriya and Jun-ichi Yamakawa and T. Takahashi and L. Shen and T. Kanda},
  journal={International journal of cardiology},
  year={2008},
  volume={130 2},
  pages={
          131-9
        }
}
  • R. Chen, Fengxia Liang, +4 authors T. Kanda
  • Published 2008
  • Medicine
  • International journal of cardiology
  • Peroxisome proliferator-activated receptors (PPARs) alpha and gamma regulate nearly every step in cellular fatty acid uptake, utilization, oxidation, and storage pathways. They also control cell growth and migration, oxidative stress, and inflammation in the cardiovascular system. Recent studies have shown that PPARs have paradoxical effects on cardiovascular diseases, especially hypertension and heart failure. It is still unclear whether the blood pressure increases or decreases after… CONTINUE READING
    Peroxisome Proliferator-Activated Receptor-γ Is Critical to Cardiac Fibrosis
    19
    Therapeutic Implications of PPARγ in Cardiovascular Diseases
    11
    The Role of PPARγ in Cardiovascular Diseases
    7
    Activation of liver X receptors with T0901317 attenuates cardiac hypertrophy in vivo
    41
    Homocysteine and Hypertension in Diabetes: Does PPARγ Have a Regulatory Role?
    44

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 95 REFERENCES
    PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ∞ AND METABOLIC DISEASE
    527
    Peroxisome proliferator‐activated receptors in the cardiovascular system
    342
    Role of Peroxisome Proliferator-Activated Receptors in Inflammation Control
    80
    Peroxisome proliferator-activated receptors in inflammation control.
    727
    Update on PPAR agonists: The clinical significance of FIELD and PROACTIVE
    12